MedPath logo

SELEGOS TABLET 5 mg

Prescription Only
Drug type: Therapeutic
ATC code: N04BD01
Dosage form: TABLET
Route of administration: ORAL
Active ingredient: SELEGILINE HCl; SELEGILINE HCL

4.1. Therapeutic indications

SELEGOS is indicated for the treatment of Parkinson’s disease or symptomatic parkinsonism.

SELEGOS may be used alone in early Parkinson’s disease to delay the need for levodopa (with or without decarboxylase inhibitor). SELEGOS may also be used as an adjunct to levodopa (with or without decarboxylase inhibitor).

4.3. Contraindications

None.

4.2. Posology and method of administration

SELEGOS 10mg (2 tablets) daily either alone or as an adjunct to levodopa or levodopa/peripheral decarboxylase inhibitor.

SELEGOS may be administered either as a single dose in the morning or in two divided doses of 5mg taken at breakfast and lunch.

When SELEGOS is added to a levodopa regimen it is possible to reduce the levodopa dosage by an average of 30 percent.

Registrant
MEDOCHEMIE SINGAPORE PTE. LTD.
Approval Date
1996-04-30
Approval Number
SIN08681P
Manufacturer
MEDOCHEMIE LTD
Licence Holder
MEDOCHEMIE SINGAPORE PTE. LTD.